Cited by 434Iron Metabolism and DisordersNeurological diseases and metabolismFerroptosis and cancer prognosis

The DOI matches its Crossref record; 226 of the 226 references it cites were found in a registry or an index.

Haemochromatosis

Open access
Brissot, Pierre, Pietrangelo, Antonello, Adams, Paul C., de Graaff, Barbara, McLaren, Christine E., Loréal, Olivier·2018·Nature Reviews Disease Primers

Abstract

Haemochromatosis is defined as systemic iron overload of genetic origin, caused by a reduction in the concentration of the iron regulatory hormone hepcidin, or a reduction in hepcidin-ferroportin binding. Hepcidin regulates the activity of ferroportin, which is the only identified cellular iron exporter. The most common form of haemochromatosis is due to homozygous mutations (specifically, the C282Y mutation) in HFE, which encodes hereditary haemochromatosis protein. Non-HFE forms of haemochromatosis due to mutations in HAMP, HJV or TFR2 are much rarer. Mutations in SLC40A1 (also known as FPN1; encoding ferroportin) that prevent hepcidin-ferroportin binding also cause haemochromatosis. Cellular iron excess in HFE and non-HFE forms of haemochromatosis is caused by increased concentrations of plasma iron, which can lead to the accumulation of iron in parenchymal cells, particularly hepatocytes, pancreatic cells and cardiomyocytes. Diagnosis is noninvasive and includes clinical examination, assessment of plasma iron parameters, imaging and genetic testing. The mainstay therapy is phlebotomy, although iron chelation can be used in some patients. Hepcidin supplementation might be an innovative future approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrdp.2018.16

Cites

226 of 226 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 223 references

Research works printed but not linked: 2

  1. Strachan, A. Haemosiderosis and haemochromatosis in South African natives with a comment on etiology of haemochrmatosis. Thesis, Univ. Glasgow (1929).
  2. Ware, J. et al. User's Manual for the SF36v2 Health Survey 2nd edn (QualityMetric, Lincoln RI, 2007).

Cited by

Sorted by citations

Items 201–300 of 434

Metadata

Authors
Brissot, P., Pietrangelo, A., Adams, P. C., de Graaff, B., McLaren, C. E., & Loréal, O.
Affiliations
  • Inserm (FR)
  • Azienda Ospedaliero-Universitaria di Modena (IT)
  • Western University (CA)
  • University of California, Irvine (US)
Corresponding author
Brissot, Pierre
Venue
Nature Reviews Disease Primers
Published
2018-04-05
Volume
4
Issue
1
Pages
18016-18016
ISSN
2056-676X (ISSN-L)
OpenAlex
W4232013301
Cited by
430
References
223
Citations by year
2026: 35 · 2025: 44 · 2024: 64 · 2023: 54 · 2022: 74 · 2021: 69 · 2020: 42 · 2019: 24 · 2018: 11
FWCI
6.11
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Disease Primers (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • eCite Digital Repository (University of Tasmania) (submittedVersion)
  • UTAS Research Repository (submittedVersion)
  • HAL (submittedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
Funders
National Cancer Institute (P30CA062203)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
hemochromatosis, iron overload, hepcidin, ferroportin, HFE C282Y mutation, hemojuvelin, transferrin receptor 2, SLC40A1, iron metabolism, phlebotomy, iron chelation, diagnosis, clinical management, quality of life
MeSH terms
Ferroportin, Hemochromatosis, Humans, Iron, Magnetic Resonance Imaging, Mass Screening, Polymorphism, Genetic, Quality of Life, Chelation Therapy, Phlebotomy, Cation Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review